Out-of-pocket expenses and their burden in patients with rheumatoid arthritis
- PMID: 19877107
- DOI: 10.1002/art.24724
Out-of-pocket expenses and their burden in patients with rheumatoid arthritis
Abstract
Objective: To describe and understand the burden of out-of-pocket expenses in patients with rheumatoid arthritis (RA).
Methods: We studied out-of-pocket expenses and their burden in 8,545 US patients with RA. We determined direct medical costs, out-of-pocket expenses, the burden of out-of-pocket expenses, household income, and measures of RA severity and outcome. In addition, patients were classified into 3 groups based on the level of burden caused by out-of-pocket expenses: no or limited problem (I am able to pay the bills without much problem); moderate problem (paying the bills takes away some money I need for other activities); and a great problem (I can't purchase all of the medications or medical care that I need).
Results: A total of 43.6% of patients reported problems paying medical bills after insurance payments and 9.0% reported severe or great problems. Problems with expenses were associated with measures of RA severity, but also and particularly with lower household income and absence of health insurance. The proportion of household income that was consumed by out-of-pocket spending for the 3 groups was 2.4%, 7.2%, and 19.2%, respectively, and the percentage of patients meeting the 185% poverty level for these groups was 12.3%, 24.4%, and 51.3%, respectively.
Conclusion: The out-of-pocket burden is substantial, particularly in those <65 years of age. Out-of-pocket expenses exert their severity predominantly on those with the most severe RA who have the least ability to pay. Household income is the primary determinant of out-of-pocket burden, followed by RA severity, and type of health insurance.
Comment in
-
Health insurance and out-of-pocket expenses.Arthritis Rheum. 2009 Nov 15;61(11):1467-9. doi: 10.1002/art.24949. Arthritis Rheum. 2009. PMID: 19877082 No abstract available.
Similar articles
-
Out-of-pocket health expenses for Medicaid and other poor and near-poor persons in 1980.Natl Med Care Util Expend Surv B. 1985 Aug;(4):1-52. Natl Med Care Util Expend Surv B. 1985. PMID: 10313450
-
[A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].Ryumachi. 2002 Feb;42(1):23-39. Ryumachi. 2002. PMID: 11925904 Japanese.
-
Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.Arthritis Rheum. 2003 Oct;48(10):2750-62. doi: 10.1002/art.11439. Arthritis Rheum. 2003. PMID: 14558079
-
What are the economic consequences for households of illness and of paying for health care in low- and middle-income country contexts?Soc Sci Med. 2006 Feb;62(4):858-65. doi: 10.1016/j.socscimed.2005.07.001. Epub 2005 Aug 15. Soc Sci Med. 2006. PMID: 16099574 Review.
-
The burden of illness of rheumatoid arthritis.Clin Rheumatol. 2011 Mar;30 Suppl 1:S3-8. doi: 10.1007/s10067-010-1634-9. Epub 2011 Feb 26. Clin Rheumatol. 2011. PMID: 21359507 Review.
Cited by
-
Patient-physician discussions about costs: definitions and impact on cost conversation incidence estimates.BMC Health Serv Res. 2016 Mar 31;16:108. doi: 10.1186/s12913-016-1353-2. BMC Health Serv Res. 2016. PMID: 27036177 Free PMC article.
-
Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction.RMD Open. 2021 Apr;7(1):e001566. doi: 10.1136/rmdopen-2021-001566. RMD Open. 2021. PMID: 33811177 Free PMC article.
-
The Autoimmune Ecology.Front Immunol. 2016 Apr 26;7:139. doi: 10.3389/fimmu.2016.00139. eCollection 2016. Front Immunol. 2016. PMID: 27199979 Free PMC article. Review.
-
Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA).BMJ Open. 2018 Feb 28;8(2):e019007. doi: 10.1136/bmjopen-2017-019007. BMJ Open. 2018. PMID: 29490959 Free PMC article. Clinical Trial.
-
The association between social determinants of health and all-cause, cardiovascular mortality in US rheumatoid arthritis: a cohort study of NHANES.BMC Public Health. 2025 Apr 22;25(1):1491. doi: 10.1186/s12889-025-22706-3. BMC Public Health. 2025. PMID: 40264100 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical